We’ve written about some questionable “clinical trials” recruiting patients in Canada recently, so it only makes sense to follow-up with some hopeful news about a legitimate, regulator-approved trial that launched this past week.
Dr. Mark Freedman, Senior Scientist of the Neuroscience Program at the Ottawa Hospital Research Institute, is leading the Canadian trial, which will determine the safety and efficacy of using autologous mesenchymal stem cells to treat multiple sclerosis. The trial is named MESCAMS (MEsenchymal Stem Cell therapy for CAnadian MS patients), and is expected to involve 200 patients globally–including 40 in Canada, 20 of whom will be at the Ottawa Hospital Research Institute and the other 20 at Winnipeg’s Health Sciences Centre.
It’s early on, but the capacity of mesenchymal stem cells to reduce inflammation and potentially promote repair has many hopeful–and the best part is that the study is thorough, controlled and based on robust, peer-reviewed research.
Latest posts by Peter Raaymakers (see all)
- Right Turn: A lesson in blood development - February 27, 2015
- Right Turn: Multiple sclerosis clinical trial begins in Ottawa - January 30, 2015
- Right Turn: How your New Year’s Resolution works - January 2, 2015